Vivus’ Qnexa Combo For Obesity Needs FDA ‘Persuasion’ To Take First-Line In Diabetes
This article was originally published in The Pink Sheet Daily
Executive Summary
CEO hails positive Phase III data, but not all analysts are convinced.
You may also be interested in...
Arena, Like Rivals, Greets Mixed Phase III Obesity Results With Brave Face
Arena's release this week of surprisingly disappointing results for its obesity drug lorcaserin raises more questions about what "efficacy" means in the highly competitive space, and about the flexibility of FDA guidance for weight-management products
Arena, Like Rivals, Greets Mixed Phase III Obesity Results With Brave Face
Arena's release this week of surprisingly disappointing results for its obesity drug lorcaserin raises more questions about what "efficacy" means in the highly competitive space, and about the flexibility of FDA guidance for weight-management products
Arena Defends Obesity Drug After Phase III BLOOM Wilts
Arena is playing up the robust safety profile and approvability of its obesity drug lorcaserin after unveiling lackluster efficacy results from the Phase III BLOOM trial